Novartis AG

Effects of behavioural exercise therapy on the effectiveness of multidisciplinary rehabilitation for chronic non-specific low back pain: a randomised controlled trial (2021) Semrau J, Hentschke C, Peters S, Pfeifer K Journal article Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis (2021) Pournara E, Kormaksson M, Nash P, Ritchlin CT, Kirkham BW, Ligozio G, Pricop L, et al. Journal article Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE (2021) D'Agostino MA, Schett G, Lopez-Rdz A, Senolt L, Fazekas K, Burgos-Vargas R, Maldonado-Cocco J, et al. Journal article A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP) (2021) Binder M, Meyer O, Rummel M, Nimmerjahn F, Tesanovic T, Sauer T, Matzdorff A Conference contribution Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes - Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Henes J, Kortus-Goetze B, Kallinich T, Oommen PT, Rech J, Weller-Heinemann F, et al. Conference contribution Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS)-30-months Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Conaghan P, Naredo E, Carron P, Burgos-Vargas R, et al. Conference contribution Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Guerrero C, Hanova P, Cazenave T, Stoenoiu MS, et al. Conference contribution Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial (2021) Venhoff N, Schmidt W, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study (2021) Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution